ロード中...
Ivosidenib: First Global Approval
Ivosidenib (Tibsovo(®)) is a small molecule, orally available inhibitor of mutated cytosolic isocitrate dehydrogenase 1 (IDH1) that is being developed by Agios Pharmaceuticals for the treatment of cancer in patients with IDH1 mutations. The mutated form of the IDH1 enzyme produces a metabolite, 2-hy...
保存先:
| 出版年: | Drugs |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6315051/ https://ncbi.nlm.nih.gov/pubmed/30209701 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-018-0978-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|